Similar articles

• Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

  Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF; QuANTUM-First Study Group. Erba HP, et al. Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25. Lancet. 2023. PMID: 37116523 Clinical Trial.
• Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.

  Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. Altman JK, et al. Am J Hematol. 2018 Feb;93(2):213-221. doi: 10.1002/ajh.24974. Epub 2017 Dec 4. Am J Hematol. 2018. PMID: 29139135 Free PMC article. Clinical Trial.
• Quizartinib for the treatment of acute myeloid leukemia.

  Garcia-Horton A, Yee KW. Garcia-Horton A, et al. Expert Opin Pharmacother. 2020 Dec;21(17):2077-2090. doi: 10.1080/14656566.2020.1801637. Epub 2020 Aug 9. Expert Opin Pharmacother. 2020. PMID: 32772726 Review.
• Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.

  Usuki K, Handa H, Choi I, Yamauchi T, Iida H, Hata T, Ohwada S, Okudaira N, Nakamura K, Sakajiri S. Usuki K, et al. Int J Hematol. 2019 Dec;110(6):654-664. doi: 10.1007/s12185-019-02709-8. Epub 2019 Jul 29. Int J Hematol. 2019. PMID: 31359361 Clinical Trial.
• The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.

  Marconi G, Giannini MB, Bagnato G, Simonetti G, Cerchione C, Mosquera Orgueira A, Musuraca G, Martinelli G. Marconi G, et al. Expert Opin Drug Saf. 2021 Jul;20(7):791-799. doi: 10.1080/14740338.2021.1913120. Epub 2021 Apr 14. Expert Opin Drug Saf. 2021. PMID: 33853481 Review.